The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 ...

Depending on the Phase I trials’ outcomes, Spyre plans to advance the SPY002 programme into Phase II development next year.

The shorter the half-life, the more often the patient must ... If there is no evidence that steady-state pharmacokinetics are important for psychotropic medications, why do we seem to live by ...

On December 2, 2024, Apogee Therapeutics, a clinical-stage biotechnology company, released a press release detailing the significant advancements made in its novel biologic programs for Inflammatory ...

Preclinical data for both SPY002 molecules demonstrate picomolar potency and potential for quarterly or twice-yearly dosing, suggesting opportunity for improved efficacy and convenience over ...

Despite a rough year, with a -65.45% YTD decline, Serina’s recent financing deal and innovative pipeline suggest that the company is poised for a comeback. Investors will be closely watching the ...

Results: The pharmacokinetics of intravenous fentanyl ... with a lag of approximately 5 minutes and a half-life of approximately 6.5 minutes. Interpatient absorption variability was approximately ...

Enhanced half-life of genetically engineered human IgG1 ... Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol 602:93-104. PMID: 20012394.

The past 10 years have seen an expansion in treatment possibilities for people with haemophilia, driven by the need for better protection against bleeding episodes, more efficient prevention of joint ...

Peer-reviewed publication features positive results from multiple ascending dose (MAD) portion of Phase 1 MBX 2109 study in ...

ProLynx Inc., a biotechnology company developing proprietary systems to extend the half-life, improve efficacy, and reduce toxicities of important therapies, today announced that research of the ...

Study highlights the safety and early bactericidal activity of quabodepistat when combined with delamanid, bedaquiline, or ...